AcelRx stock: buy or sell?

ACRX stock price: $2.96 3.50% At close on May 21st, 2019

Updated on:
May 21st, 2019

1

AcelRx shares skyrocketed 3.50% to $2.96 today. On Thursday ACRX plummed a dreadful -10.75%.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.

Should I buy AcelRx stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, AcelRx Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean ACRX will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is AcelRx Pharmaceuticals stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we detected 2 ratings published for ACRX stock in the last 30 days.

Is ACRX a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-9LADENBURG THALM/SH SHn/aBuy
2019-2-15Credit Suisse Groupn/aOutperform

AcelRx stock analysis

Daily outlook

AcelRx shares skyrocketed 3.50% to $2.96 today.

Shares of AcelRx Pharmaceuticals skyrocketed a cool 3.50% and closed at $2.96. In the last 8 days when ACRX stock price broke down the SMA200d line, it slid $-0.35 per share (-10.57%). ACRX marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $3.37 would break this short term down trend and open possibilities for reversing this situation.

ACRX stock chart (daily)

Weekly outlook

After sliding a bloodcurdling -14.14% in a week last week, AcelRx closed this week at $2.96 and stepped up a fine 2.07%. Late April ACRX skyrocketed an amazing 13.99% in just one week.

Weekly chart tells us that price is in a simple uptrend, tested $2.76 level and now climbing back aiming its last top at $4.09. Since last week, when ACRX stock price broke down the 40-weeks moving avarage line, it slid $-0.35 per share (-10.57%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.

ACRX stock chart (weekly)

AcelRx stock price history

AcelRx IPO was on February 11th, 2011 at $5.00 per share1. Since then, ACRX stock declined a -40.80%, with a yearly average of -5.10%.

1: Adjusted price after possible price splits or reverse-splits.

AcelRx stock historical price chart

ACRX stock reached 52-week highs on November at $5.05, and all-time highs 2014-03-06 with a price of 13.64.

AcelRx stock price target is $10.00

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. Currently, only 1 price forecast for AcelRx Pharmaceuticals stock was published in the last month:
ACRX stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-9LADENBURG THALM/SH SHReiteratesn/a$10.00-
(in average)$0.00$10.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, AcelRx Pharmaceuticals missed the expectations of the analysts and posted an awful EPS of $-0.18 per share when experts were expecting $-0.20.
ACRX earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.34n/a
2017-Q2-n/a-0.29n/a
2017-Q32017-10-30-0.27n/an/a
2017-Q42018-03-08-0.2-0.2n/a
2018-Q12018-05-09-0.24-0.23n/a
2018-Q22018-08-02-0.19-0.2n/a
2018-Q32018-11-02-0.2-0.21n/a
2018-Q42019-03-07-0.2-0.18n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a frightening slide of -73.10% to $2.15 M dollars. Similarly, its earnings margin (compared to sales) plummed to -2,191.96%, that is $-47.15 million.

ACRX annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$30 M-$-23.43 M-79.4%-
2014$5.22 M-82.32%$-33.35 M-639.3%42.35%
2015$19 M269.24%$-24.40 M-126.7%-26.85%
2016$17 M-9.89%$-43.16 M-248.6%76.88%
2017$8.00 M-53.94%$-51.51 M-644.3%19.35%
2018$2.15 M-73.10%$-47.15 M-2192.0%-8.46%

Quarterly financial results

AcelRx Pharmaceuticals posted $0.61 M in revenues for 2018-Q4, a 62.60% improvement compared to previous quarter. Reported quarter earnings marked $-12.56 M with a profit margin of -2,048.61%. Profit margin rocketed a 1,255.90% compared to previous quarter when profit margin was -3,304.51%. When comparing revenues to same quarter last year, AcelRx sales marked a bloodcurdling correction and plummed a -17.16%.
ACRX quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q1$3.11 M-$-15.55 M-500.0%-
2017-Q2$2.66 M-14.47%$-13.06 M-491.0%-16.01%
2017-Q3$1.49 M-44.10%$-13.01 M-875.1%-0.36%
2017-Q4$0.74 M-50.24%$-9.89 M-1335.8%-24.04%
2018-Q1$0.34 M-53.65%$-11.59 M-3379.6%17.27%
2018-Q2$0.82 M138.48%$-10.54 M-1288.6%-9.07%
2018-Q3$0.38 M-53.91%$-12.46 M-3304.5%18.19%
2018-Q4$0.61 M62.60%$-12.56 M-2048.6%0.80%

AcelRx ownership

When you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.

AcelRx shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 11.62% of all shares.

In case of AcelRx stock, 19.73% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ACRX stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

ACRXBDSICARADRRXINSY
Market cap$233.6 M$401.2 M$755.3 M$118.5 M$67.7 M
Total shares78.9 M87.4 M39.8 M162.4 M74.4 M
Float shares77.7 M59.9 M35.1 M155.9 M27.1 M
  - Institutional holdings (%)19.7%58.8%62.4%46.1%24.4%
  - Insider holdings (%)11.6%6.0%2.9%4.0%63.7%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

AcelRx summary

Tuesday, May 21st, 2019
Open$2.86
Close$2.96
Day range$2.86 - $3.01
Previous close$2.86
Session gain3.50%
Average true range$0.21
50d mov avg$3.36
100d mov avg$3.08
200d mov avg$3.22
Daily patternlb06a
Weekly pattern lb01a

AcelRx performance

To measure stock performance is always good to benchmark with competitors or related stocks. We picked BioDelivery Sciences International, Cara Therapeutics, DURECT, Insys Therapeutics, The Medicines and Recro Pharma as the bechmarking frame for AcelRx Pharmaceuticals stock.
Stock3m6m12m
ACRXAcelRx Pharmaceut...-7.50%-18.46%-7.50%
BDSIBioDelivery Scien...-8.20%26.45%91.25%
CARACara Therapeutics12.09%2.26%11.63%
DRRXDURECT-7.59%-13.10%-62.94%
INSYInsys Therapeutic...-85.23%-86.44%-86.73%
MDCOThe Medicines38.37%60.38%2.34%
REPHRecro Pharma9.21%41.11%64.50%

AcelRx competitors

One check before trading any stock is to review a list of its competitors, in this case for AcelRx. We chose 6 companies as AcelRx competitors as they are in the same industry or have similar market objectives.